INNOPRAN XL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INNOPRAN XL (INNOPRAN XL).
Propranolol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) that competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. It also blocks beta-2 receptors in bronchial and vascular smooth muscle, leading to bronchoconstriction and vasoconstriction.
| Metabolism | Primarily hepatic via CYP2D6 and CYP1A2; also glucuronidation. Active metabolites include 4-hydroxypropranolol. |
| Excretion | Primarily renal excretion of unchanged drug and inactive metabolites; approximately 60-75% of a dose is recovered in urine as parent drug and metabolites, with <5% in feces. |
| Half-life | Terminal elimination half-life is 10-12 hours for immediate-release; for Innopran XL (extended-release), effective half-life is approximately 24-30 hours due to prolonged absorption, allowing once-daily dosing. |
| Protein binding | Approximately 90-95% bound primarily to albumin; also binds to alpha-1-acid glycoprotein. |
| Volume of Distribution | Approximately 3-5 L/kg, indicating extensive extravascular distribution, including into the central nervous system. |
| Bioavailability | Oral (extended-release): approximately 25-30% due to extensive first-pass metabolism; immediate-release: about 30-40%; food may increase bioavailability of extended-release by 10-15%. |
| Onset of Action | Oral (extended-release): 2-4 hours to achieve therapeutic beta-blockade; peak effect at 6-8 hours. |
| Duration of Action | Approximately 24 hours with extended-release formulation; clinical effect may persist beyond 24 hours in some patients; used for once-daily dosing in hypertension and angina. |
Oral, 80 mg once daily, increased at weekly intervals to 160 mg once daily, then to 240 mg once daily if needed.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl 30-59 mL/min: reduce dose by 50%; CrCl <30 mL/min: reduce dose by 75% or use alternative therapy. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | Start at 40 mg once daily; titrate cautiously due to increased sensitivity and reduced renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for INNOPRAN XL (INNOPRAN XL).
| Breastfeeding | Propranolol (active ingredient) is excreted in breast milk; M/P ratio ~0.5-1.5. Infant dose <1% maternal weight-adjusted dose. AAP compatible but monitor infant for bradycardia, hypoglycemia. Caution in preterm/compromised infants. |
| Teratogenic Risk | First trimester: Based on propranolol, risk of fetal bradycardia and hypoglycemia. No major teratogenicity established, but caution advised. Second trimester: Continued risk of bradycardia; monitor fetal heart rate. Third trimester: Risk of neonatal bradycardia, hypoglycemia, respiratory depression at delivery. Avoid near term. |
■ FDA Black Box Warning
No FDA black box warning for propranolol specifically; however, beta-blockers may exacerbate angina upon abrupt cessation, and use in ischemic heart disease requires gradual dose reduction.
| Serious Effects |
["Cardiogenic shock","Sinus bradycardia","Heart block greater than first degree","Bronchial asthma","Decompensated heart failure","Known hypersensitivity to propranolol"]
| Precautions | ["Abrupt discontinuation may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease.","May mask signs of hyperthyroidism or hypoglycemia.","Use with caution in asthma or COPD (bronchospasm).","May worsen peripheral vascular disease.","May cause bradycardia, hypotension, or heart failure.","Caution in patients with diabetes mellitus (masks tachycardia of hypoglycemia).","May cause dizziness or fatigue; avoid driving if affected."] |
| Food/Dietary | Take with or without food; high-fat meals may increase absorption. Avoid grapefruit and grapefruit juice, as they may alter drug metabolism. Limit alcohol intake, which may potentiate hypotension and CNS depression. Maintain adequate fluid intake but avoid sudden dietary changes that affect potassium or sodium levels. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate and blood pressure; fetal heart rate and growth; neonatal heart rate and glucose after delivery. Consider fetal echocardiography if prolonged use. |
| Fertility Effects | No known direct effects on fertility. In women, menstrual irregularities reported rarely. In males, potential for sexual dysfunction (erectile dysfunction, decreased libido) may indirectly affect fertility. |
| Clinical Pearls | Innopran XL (propranolol extended-release) is a non-selective beta-blocker used for hypertension, angina, migraine prophylaxis, and essential tremor. Due to its lipophilicity, it crosses the blood-brain barrier, causing CNS side effects like fatigue and vivid dreams. Taper dose over 1-2 weeks to avoid rebound hypertension or angina. Monitor heart rate and blood pressure; adjust dose in hepatic impairment. Avoid in asthma, COPD, bradycardia, and decompensated heart failure. |
| Patient Advice | Take exactly as prescribed, usually once daily, with or without food. Swallow capsule whole; do not crush or chew. · Do not stop abruptly; sudden discontinuation can cause chest pain, heart attack, or worsening of blood pressure. · Avoid driving or operating machinery if you feel dizzy or drowsy. This is more common at start of therapy. · Report slow heart rate, fainting, shortness of breath, or swelling of hands/feet to your healthcare provider. · This medication may mask symptoms of low blood sugar (shakiness, fast heartbeat). Monitor blood sugar closely if diabetic. · Limit alcohol consumption, as it can increase dizziness and drowsiness. · Use caution when taking with other medications, especially NSAIDs and other blood pressure drugs. |